The 13 Wall Street analysts covering MiniMed Group, Inc. hold a median 12-month price target of $21 — +0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores MiniMed Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (52): Analysts have, on balance, been raising their forecasts.
Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MMED, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +0.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | UBS | Assumes | Buy | $25 |
| 4 June 2026 | Wells Fargo | Maintains | Overweight | $26 → $22 |
| 4 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 18 May 2026 | B of A Securities | Maintains | Buy | — |
| 12 May 2026 | Benchmark | Initiates | Buy | — |
| 1 Apr 2026 | Barclays | Initiates | Overweight | — |
| 31 Mar 2026 | B of A Securities | Initiates | Buy | — |
| 31 Mar 2026 | BTIG | Initiates | Buy | — |
| 31 Mar 2026 | Citigroup | Initiates | Buy | — |
| 31 Mar 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 31 Mar 2026 | Mizuho | Initiates | Outperform | — |
| 31 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 31 Mar 2026 | Piper Sandler | Initiates | Neutral | — |
| 31 Mar 2026 | Wells Fargo | Initiates | Overweight | — |
| 31 Mar 2026 | William Blair | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MMED appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 55% of US stocks
Cheaper than 55% of US stocks
Cheaper than 16% of US stocks
Higher than 64% of US stocks
Higher than 71% of US stocks
Higher than 61% of US stocks
Higher than 19% of US stocks
Higher than 36% of US stocks
Higher than 57% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MiniMed Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MiniMed Group's MiniMed Flex is now shipping in the U.S., paired with Abbott's 15-day Instinct sensor. The system combines discreet app control with automated insulin delivery.
Why it matters — This product launch expands MiniMed's U.S. automated insulin delivery offerings with a new sensor partnership.
MiniMed announced that its MiniMed Flex™ system is now commercially shipping in the U.S., pairing the small app-controlled insulin pump with the Instinct sensor made by Abbott. The system offers up to 15 days of sensor wear and combines discreet design with proven automation to reduce the work and interruptions of diabetes management.
Why it matters — For MMED watchers, this marks the U.S. commercial launch of a new flagship product line, potentially broadening the company's product offering in the insulin pump and sensor market.
MiniMed Group, Inc. (MMED) has secured Medicare coverage for its Flex insulin pump system, expanding access to Medicare beneficiaries for its app-controlled pump and automated insulin delivery technology.
Why it matters — This Medicare coverage decision opens up a significant patient population to MMED's Flex technology, potentially driving adoption and revenue growth.
The article discusses MiniMed Group, a Medtronic spin-off, noting its double-digit revenue growth driven by strong international adoption, expanding CGM attach rates, and product launches. It also mentions gross margin compression and widened net losses in FY 2026, offset by robust liquidity from IPO proceeds supporting product rollouts and operational improvements.
Why it matters — A MMED watcher would care because the piece highlights both the company's growth catalysts and its near-term financial challenges, offering a balanced view of its post-IPO trajectory.
The 13 Wall Street analysts covering MiniMed Group, Inc. have a median 12-month price target of $21, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 13 analysts covering MiniMed Group, Inc., 11 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks MiniMed Group, Inc. 2 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, MiniMed Group, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (52 of 100).
No one can know that. What the data says: the median 12-month target from 13 analysts implies +0.3% from the last close, and Ticker Nerd's factor model ranks MiniMed Group, Inc. 2 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MiniMed Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.
MiniMed Group, Inc. is a medical technology company focused on diabetes management solutions.
The most recent item we track (Zacks Investment Research, 20 Aug 2026): "MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor". MiniMed Group's MiniMed Flex is now shipping in the U.S., paired with Abbott's 15-day Instinct sensor. The system combines discreet app control with automated insulin delivery.
MiniMed Group, Inc. is a medical technology company focused on diabetes management solutions. MiniMed Group develops, manufactures, and markets insulin pumps, continuous glucose monitoring systems, smart insulin pens, infusion sets, related consumables, and digital health software used to support people with Type 1 and insulin-requiring Type 2 diabetes. Its product portfolio centers on automated insulin delivery and smart multiple daily injection systems, combining glucose sensing, dosing algorithms, and connected data tools into integrated care platforms. The company serves a global customer base through a broad range of diabetes technologies and services that help patients and healthcare providers monitor glucose levels and manage insulin therapy more effectively. Headquartered in Northridge, California, MiniMed Group plays a specialized role in the medical device market as a provider of comprehensive diabetes care solutions.
CEO Ms. Que Thanh Dallara · 8,000 employees · United States · https://www.minimed.com